Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.44 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16242365 | 0.88 | KCNJ1 (0.40) | GPR119KCNJ1MEN1ALDH1A1ALOX15 | |
| SCHEMBL16242397 | 0.88 | KCNJ1 (0.40) | GPR119KCNJ1MEN1ALDH1A1ALOX15 | |
| SCHEMBL3690472 | 0.88 | KCNJ1 (0.40) | GPR119KCNJ1MEN1ALDH1A1ALOX15 | |
| SCHEMBL4279095 | 0.83 | GPR119 (0.41) | GPR119KCNJ1HDAC1RETMEN1 | |
| SCHEMBL16258810 | 0.83 | GPR119 (0.41) | GPR119KCNJ1HDAC1RETMEN1 | |
| SCHEMBL7588343 | 0.83 | GPR119 (0.41) | GPR119KCNJ1HDAC1RETMEN1 | |
| SCHEMBL7602450 | 0.83 | GPR119 (0.41) | GPR119KCNJ1HDAC1RETMEN1 | |
| SCHEMBL4279093 | 0.83 | GPR119 (0.41) | GPR119KCNJ1HDAC1RETMEN1 | |
| SCHEMBL3694315 | 0.83 | GPR119 (0.48) | GPR119KCNJ1 | |
| SCHEMBL7593060 | 0.83 | GPR119 (0.49) | GPR119KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185544-B1 | N-AZACYCLIC SUBSTITUTED PYRROLE, PYRAZOLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS INC (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2185544-B1 | N-AZACYCLIC SUBSTITUTED PYRROLE, PYRAZOLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS INC (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8846675-B2 | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846675-B2 | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846675-B2 | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20120322804-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC. | 2012-12-20 | — | — | US | disclosed |
| US-20120322804-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC. | 2012-12-20 | — | — | US | disclosed |
| US-20120322804-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC. | 2012-12-20 | — | — | US | disclosed |
| US-8183381-B2 | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | METABOLEX INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183381-B2 | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | METABOLEX INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183381-B2 | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | METABOLEX INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090137590-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137590-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137590-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2009014910-A2 | N-AZACYCLIC SUBSTITUTED PYRROLE, PYRAZOLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 RECEPTOR FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137590-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | GPR119 1/4885KCNJ1 2412/4885HDAC1 3071/4885 |
| US-20120322804-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | GPR119 1/4885KCNJ1 2412/4885HDAC1 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.